Publications by authors named "Edwina Scott"

Claim this Profile
D
Distribution and metabolism of [14C]-resveratrol in human prostate tissue after oral administration of a "dietary-achievable" or "pharmacological" dose: what are the implications for anticancer activity?
Hong Cai, Edwina N Scott, Robert G Britton, Emma Parrott, Ted J Ognibene

Am J Clin Nutr· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cancer chemoprevention: Evidence of a nonlinear dose response for the protective effects of resveratrol in humans and mice.
Hong Cai, Edwina Scott, Abeer Kholghi, Catherine Andreadi, Alessandro Rufini

Sci Transl Med· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prolonged biologically active colonic tissue levels of curcumin achieved after oral administration--a clinical pilot study including assessment of patient acceptability.
Glen R B Irving, Lynne M Howells, Stewart Sale, Ines Kralj-Hans, Wendy S Atkin, Edwina N Scott

Cancer Prev Res (Phila)· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study.
Jens Samol, Malcolm Ranson, Edwina Scott, Euan Macpherson, James Carmichael

Invest New Drugs· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Resveratrol in human cancer chemoprevention--choosing the 'right' dose.
Edwina Scott, William P Steward, Andreas J Gescher, Karen Brown

Mol Nutr Food Res· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical trials of resveratrol.
Ketan R Patel, Edwina Scott, Victoria A Brown, Andreas J Gescher, William P Steward

Ann N Y Acad Sci· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel VEGF signalling inhibitors: how helpful are biomarkers in their early development?
Joanna Wood, Edwina Scott, Anne L Thomas

Expert Opin Investig Drugs· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI), in patients with advanced solid tumours.
Edwina N Scott, Anne L Thomas, L Rhoda Molife, Samreen Ahmed, Sarah Blagden

Cancer Chemother Pharmacol· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of dietary phytochemical chemopreventive agents: biomarkers and choice of dose for early clinical trials.
Edwina N Scott, Andreas J Gescher, William P Steward, Karen Brown

Cancer Prev Res (Phila)· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Surgical bypass vs. endoscopic stenting for pancreatic ductal adenocarcinoma.
Edwina N Scott, Giuseppe Garcea, Helena Doucas, Will P Steward, Ashley R Dennison

HPB (Oxford)· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vatalanib: the clinical development of a tyrosine kinase inhibitor of angiogenesis in solid tumours.
Edwina N Scott, Gerold Meinhardt, Christian Jacques, Dirk Laurent, Anne L Thomas

Expert Opin Investig Drugs· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis